Is MRK a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

12,594 people get MRK articles and Market Currents by email alert.

Get email alerts on MRK »

HEADLINES:

Bristol Myers Squibb And The New Wave Of Cancer Drugs
Peter Geschek • Mon, May 20
Merck & Co., Inc. Management Presents at UBS Global Healthcare Conference (Transcript)
Mon, May 20
Oramed Sweeps Past Worldwide Giants With The First Trial Of Orally Delivered Insulin
Sharon di Stefano • Sun, May 19 • 45 Comments
Oncothyreon A Speculative Buy
Northwest Trader • Fri, May 17 • 4 Comments
Global Health, Development and Business Leaders Announce New Innovative Financing Partnership to Deliver Essential Health Supplies More Quickly and Efficiently

Business Wire (Fri, 8:30AM)
Bristol-Myers, Merck And Roche: R&D Finds Golden Pill, So Buy
John Tobey • Fri, May 17 • 6 Comments
The Dow Hits All-Time Highs, But The Truth Is It Remains Cheaply Valued
Chuck Carnevale • Thu, May 16 • 59 Comments
Merck Prices $ 6.5 Billion Debt Offering

Business Wire (Wed, 6:29PM)
Large Hedge Fund Levin Capital's Top Stock Picks
Insider Monkey • Wed, May 15
Can Merck's Pipeline Offset The Pain From Major Patent Expirations?
Trefis • Tue, May 14
10 Hot Healthcare Dogs Probe 6% To 38.2% Gains In April
Fredrik Arnold • Mon, May 13 • 2 Comments
Baby Boomers Are Money-Making Machines For Big Pharma
Tedra DeSue • Mon, May 13 • 2 Comments
Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
C.R. Jackson • Sun, May 12 • 2 Comments
Letting Statistics Help You See What You Want To See
George Acs • Sun, May 12 • 7 Comments
Review Of Depomed's First Quarter 2013 Results
Jason Napodano • Thu, May 9 • 3 Comments
Merck's Liptruzet: A Cause For Shame?
Derek Lowe • Thu, May 9
5 Stocks This Legendary Value Investor Is Backing
Insider Monkey • Thu, May 9 • 1 Comment
Imminent Catalysts For Small Pharmaceuticals
Chemistfrog • Tue, May 7 • 9 Comments
An Update On Pfizer's Recently Approved Drugs
Jon Crowley • Tue, May 7 • 8 Comments
Merck: A Negative Growth Story
Jeffrey To • Tue, May 7 • 12 Comments

Merck's Discount Comes At A Price
Stephen Simpson • Mon, Feb 4 • 2 Comments

Can Merck's Pipeline Offset The Pain From Major Patent Expirations?
Trefis • Tue, May 14
Merck's Liptruzet: A Cause For Shame?
Derek Lowe • Thu, May 9
Merck: A Negative Growth Story
Jeffrey To • Tue, May 7 • 12 Comments
Rating Agencies Turn Negative On Merck
Tedra DeSue • Tue, May 7 • 3 Comments
Merck Pharmaceuticals' Suvorexant: A Wake-Up Call
Healthcare Specialist • Mon, May 6 • 3 Comments
Mapping Merck: Q1 And Beyond
Vlad Deshkovich • Thu, May 2 • 8 Comments
Whisper Number Impact: Earnings Preview For Merck
WhisperNumber • Tue, Apr 30
Merck: Here Is What You Should Do At The 52-Week High
Stock Gamer • Wed, Apr 24 • 4 Comments
Merck's Promising Vaccine Empire
Peter Geschek • Fri, Apr 19 • 2 Comments
Merck & Co: Growth Will Become Stagnant
Alex Cho • Mon, Apr 8 • 6 Comments
How Much Is Merck Worth?
Efsinvestment • Wed, Mar 27 • 3 Comments
Merck: A Bright Future Ahead
Catalyst Investments • Thu, Mar 21 • 4 Comments
Merck's Struggles To Replace Singulair Lead To Biosimilars
Peter Pham • Mon, Mar 18 • 3 Comments
Merck Intensifies Efforts To Tap The Biologics Market With New R&D Head
Trefis • Wed, Mar 13 • 5 Comments
The Battle Of Big Pharma: Who Has The Better Balance Sheet, Pfizer Or Merck?
David Schauber, Jr. • Tue, Mar 12 • 6 Comments
Pengrowth Energy And Merck: Undervalued, High Dividend, And Positive Upgrades
Nick Chiu • Tue, Mar 5 • 4 Comments
5 Reasons To Avoid Merck
StockRiters • Wed, Feb 27 • 13 Comments
Merck: The Most Undervalued Company In Pharma
Timothy McIntosh • Thu, Feb 21 • 31 Comments
Merck: Enjoy This Generous Yield
Efsinvestment • Tue, Feb 19 • 2 Comments
Merck Finally Settles Over Vytorin
Derek Lowe • Fri, Feb 15 • 3 Comments

Bristol Myers Squibb And The New Wave Of Cancer Drugs
Peter Geschek • Mon, May 20
Oramed Sweeps Past Worldwide Giants With The First Trial Of Orally Delivered Insulin
Sharon di Stefano • Sun, May 19 • 45 Comments
Oncothyreon A Speculative Buy
Northwest Trader • Fri, May 17 • 4 Comments
Bristol-Myers, Merck And Roche: R&D Finds Golden Pill, So Buy
John Tobey • Fri, May 17 • 6 Comments
The Dow Hits All-Time Highs, But The Truth Is It Remains Cheaply Valued
Chuck Carnevale • Thu, May 16 • 59 Comments
Large Hedge Fund Levin Capital's Top Stock Picks
Insider Monkey • Wed, May 15
10 Hot Healthcare Dogs Probe 6% To 38.2% Gains In April
Fredrik Arnold • Mon, May 13 • 2 Comments
Baby Boomers Are Money-Making Machines For Big Pharma
Tedra DeSue • Mon, May 13 • 2 Comments
Part 1: Will Array BioPharma Become A Late-Stage Biopharmaceutical Company?
C.R. Jackson • Sun, May 12 • 2 Comments
Letting Statistics Help You See What You Want To See
George Acs • Sun, May 12 • 7 Comments
Review Of Depomed's First Quarter 2013 Results
Jason Napodano • Thu, May 9 • 3 Comments
5 Stocks This Legendary Value Investor Is Backing
Insider Monkey • Thu, May 9 • 1 Comment
Imminent Catalysts For Small Pharmaceuticals
Chemistfrog • Tue, May 7 • 9 Comments
An Update On Pfizer's Recently Approved Drugs
Jon Crowley • Tue, May 7 • 8 Comments
A Great Reason For Investment Money To Sleep
Gary Bourgeault • Tue, May 7 • 7 Comments
9 Top Healthcare Dogs Hunt 3.5% To 51.9% Gains In April
Fredrik Arnold • Mon, May 6
Netupitant Results Could Roil Tesaro In May
Richard Pearson • Mon, May 6 • 9 Comments
Cramer's Mad Money - 10 Things To Watch In The Week Ahead (5/3/13)
SA Editor Miriam Metzinger • Sun, May 5 • 4 Comments
Why Royalty And Milestone Partnership Dynamics Imply Trovagene Could Triple
Logical Assessment • Fri, May 3 • 2 Comments
Biotech Bulls Can Ignore The Warning Signs At Their Peril
EP Vantage • Thu, May 2 • 7 Comments

Merck & Co., Inc. Management Presents at UBS Global Healthcare Conference (Transcript)
Mon, May 20
Merck's CEO Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 1
Merck CEO Discusses Q4 2012 Results - Earnings Call Transcript
Fri, Feb 1 • 1 Comment
Merck & Co. Management Discusses Q3 2012 Results - Earnings Call Transcript
Fri, Oct 26, 2012
Merck & Co. Management Discusses Q2 2012 Results - Earnings Call Transcript
Fri, Jul 27, 2012
Merck's Management Host Conference on Suvorexant Phase III Data (Transcript)
Wed, Jun 13, 2012
Merck & Co.'s CEO Discusses Q1 2012 Results - Earnings Call Transcript
Fri, Apr 27, 2012
Merck & Co.'s CEO Discusses Q4 2011 Results - Earnings Call Transcript
Thu, Feb 2, 2012
Merck & Co. Inc. - Special Call
Thu, Nov 10, 2011
Merck & Co.'s CEO Discusses Q3 2011 Results - Earnings Call Transcript
Fri, Oct 28, 2011
Merck & Co.'s CEO Discusses Q2 2011 Results - Earnings Call Transcript
Fri, Jul 29, 2011
Merck & Co.'s CEO Discusses Q1 2011 Results - Earnings Call Transcript
Fri, Apr 29, 2011
Merck & Co.'s CEO Discusses Q4 2010 Results - Earnings Call Transcript
Thu, Feb 3, 2011
Merck CEO Discusses Q3 2010 Results - Earnings Call Transcript
Fri, Oct 29, 2010
Merck & Co. Q2 2010 Earnings Call Transcript
Fri, Jul 30, 2010
Merck & Co. Q1 2010 Earnings Call Transcript
Tue, May 4, 2010
Merck & Co., Inc. Q4 2009 Earnings Call Transcript
Tue, Feb 16, 2010
Merck & Co., Inc. Q3 2009 Earnings Call Transcript
Thu, Oct 22, 2009
Merck & Co. Inc. Q2 2009 Earnings Call Transcript
Tue, Jul 21, 2009
Merck F1Q09 Earnings Call Transcript
Tue, Apr 21, 2009

Market Snapshot: U.S. stocks drop, retreating from all-time highs

at MarketWatch.com (Mon, 4:38PM)
Jennifer Aniston: Movie Star Turned Hair Care Mogul

at CNBC.com (Fri, 1:43PM)
Global Health, Development and Business Leaders Announce New Innovative Financing Partnership to Deliver Essential Health Supplies More Quickly and Efficiently

Business Wire (Fri, 8:30AM)
Merck Prices $ 6.5 Billion Debt Offering

Business Wire (Wed, 6:29PM)
Big Pharma Disappoints on Revenues, Earnings

at CNBC.com (May 6, 2013)
Fear on the Floor Ahead of Jobs Report

at CNBC.com (May 2, 2013)
Earnings Watch: Updates, advisories and surprises

at MarketWatch.com (May 1, 2013)
Jim Cramer: Common Drug Stock Mistake

at CNBC.com (May 1, 2013)
Movers & Shakers: Wednesday’s movers: Facebook recovers on earnings

at MarketWatch.com (May 1, 2013)
Stocks End Near Lows: Dow, S&P Log Weakest Start to Month Since June

at CNBC.com (May 1, 2013)
Market Snapshot: U.S. stocks sink; Dow snaps 4-day win streak

at MarketWatch.com (May 1, 2013)
Wall Street Sinks as Oil Sells Off

at Fox Business (May 1, 2013)
Wall Street Thrashed Amid Mounting Economic Worries

at Fox Business (May 1, 2013)
May's OK, Worry About Later Months: Pro

at CNBC.com (May 1, 2013)
Merck Shares Slide as Sales Widely Miss Estimates

at Fox Business (May 1, 2013)
Indications: Stock futures fall as revenue disappoints

at MarketWatch.com (May 1, 2013)
Futures Flat After ADP Report, Ahead of Fed

at CNBC.com (May 1, 2013)
Stocks to Watch: Facebook, Comcast are Wednesday’s stocks to watch

at MarketWatch.com (May 1, 2013)
Futures Waver as Traders Digest Weak Data, Earnings

at Fox Business (May 1, 2013)
Merck Reports Disappointing Sales, Cuts Forecast

at CNBC.com (May 1, 2013)

MRK vs. ETF Alternatives

Company Description

On November 3, 2009, Merck & Co., Inc. (“Old Merck”) and Schering-Plough Corporation (“Schering-Plough”) completed their previously-announced merger (the “Merger”). In the Merger, Schering-Plough acquired all of the shares of Old Merck, which became a wholly-owned subsidiary of Schering-Plough... More

Sector: Healthcare

Industry: Drug Manufacturers - Major

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, May 16, 12:55 PM Oncothyreon (ONTY -20.7%) tanks today after presenting data as ASCO that showed Phase III trials of its investigational MUC1 antigen-specific cancer immunotherapy L-BLP25 didn't meet its primary objective. The trial was conducted by Merck Serono, a division of Merck (MRK -0.7%), under a license agreement with ONTY. 3 Comments [Healthcare, On the Move]
Monday, May 6, 1:36 PM Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses. Comment! [Healthcare, On the Move]
Monday, May 6, 12:30 PM Tesaro (TSRO -0.2%) feels a little heat today from a cautious post in Seeking Alpha. SA author Richard Pearson notes that the stock has more than doubled since its IPO debut last June, largely on enthusiasm for its still far-off cancer drug Niraparib. Over the near term however, the company is facing some significant challenges, particularly for its lead drug Rolapitant, a treatment for nausea and vomiting caused by the effects of chemotherapy. Merck's (MRK -1%) Emend is currently its largest competitor in the space, and will already be generic when Rolapitant comes to market. Comment! [Healthcare]
Friday, May 3, 4:09 PM The FDA has approved Merck's (MRK -0.2%) Liptruzet drug for treating elevated LDL cholesterol levels in patients with primary or mixed hyperlipidemia. Lipruzet combines two existing anti-cholesterol drugs, ezetimibe and atorvastatin. It'll be available to wholesalers next week. (PR) 3 Comments [Healthcare]
Friday, May 3, 10:50 AM Fitch revises its outlook to Negative from Positive on Merck's (MRK +0.3%) Issuer Default Rating (A+). Apparently, the temptation to fund share buybacks with debt given the favorable rate environment should be weighed against any potential deleterious effects from increased leverage: MRK "intends to use debt issuances … to repurchase $7.5B worth of shares over the next 12 months [but the company] has ample liquidity via cash on hand and operating cash flow … to complete the [buyback] without harm to the credit profile … the financing of the [buyback] program could drive debt leverage to a level that is not reflective of the 'A+' IDR," Fitch says. 1 Comment [Healthcare]
Wednesday, May 1, 7:15 AM More on Merck's (MRK) Q1: Earnings beat but revenue misses as patent expirations and unfavorable foreign exchange rates reduce worldwide sales by 9%. The company says it witnessed growth in vaccines, immunology, animal health, and consumer care products during the period. MRK also revises its guidance for the year, saying it now sees non-GAAP EPS of $3.45-3.55. Analysts expect $3.63. Shares -1% premarket. (PR) 1 Comment [Healthcare]
Wednesday, May 1, 7:01 AM Merck (MRK): Q1 EPS of $0.85 beats by $0.05. Revenue of $10.67B misses by $0.42B. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, May 1, 12:05 AM Notable earnings before Wednesday’ s open: AB, ADT, AFAM, AFSI, AGN, AH, AMT, ARW, AVA, CCJ, CHK, CLH, CLX, CMCSA, CVH, CVS, DLPH, DVN, ENR, EXAS, EXC,GRMN, GWR, H, HSP, HUM, ICE, IPGP, IQNT, IRM, JRCC, KCG, KFN, MA, MKL, MRK, NVO, PDCE, PKD, POR, PSX, RDC, RDN, SEE, SPW, TLM, TWX, VG, VIAB, VPHM Comment! [Earnings]
Tuesday, April 30, 5:30 PM Notable earnings before Wednesday’ s open: AB, ADT, AFAM, AFSI, AGN, AH, AMT, ARW, AVA, CCJ, CHK, CLH, CLX, CMCSA, CVH, CVS, DLPH, DVN, ENR, EXAS, EXC,GRMN, GWR, H, HSP, HUM, ICE, IPGP, IQNT, IRM, JRCC, KCG, KFN, MA, MKL, MRK, NVO, PDCE, PKD, POR, PSX, RDC, RDN, SEE, SPW, TLM, TWX, VG, VIAB, VPHM Comment! [Earnings]
Monday, April 29, 7:55 AM Merck (MRK) and Pfizer (PFE) enter into a 60/40 worldwide agreement to jointly develop and commercialize PFE's type 2 diabetes treatment ertugliflozin which should enter Phase III trials later this year. As part of the deal, PFE received $60M upfront and may receive additional payments in the future. (PR) 3 Comments [Healthcare]
Saturday, April 27, 10:53 PM Combining Gilead's (GILD) sofosbuvir and Bristol-Myers Squibb's (BMY) daclatasvir cures 100% of hepatitis C patients in 12 weeks (including those who failed treatment with Vertex's (VRTX) Incivek and Merck's (MRK) Victrelis) and looks to be a better treatment option for those with genotype 3 than a combo of sofosbuvir and another GILD drug ledipasvir. The problem: "GILD very clearly wants to develop in-house," one clinician tells Bloomberg. (See also: ABBV's HCV treatment successful; VRTX teams with BMY on HCV trial) 5 Comments [Healthcare]
Monday, April 22, 10:02 AM Merck (MRK -0.1%-) gives back an early pre-market gain after announcing that it's entered into a non-exclusive agreement with Bristol-Myers Squibb (BMY) to conduct Phase II clinical trials to evaluate a combination of investigational oral candidates MK-5172 and Daclatasvir for the treatment of chronic Hepatitis C. Under the terms of the agreement, MRK will conduct only the Phase II clinical trial, with further clinical development activities beyond the Phase II studies not covered under the agreement.. Comment! [Healthcare]
Wednesday, April 10, 1:37 PM Jefferies raises its price targets on big pharma names Pfizer (PFE +2.6%) ($33), Merck (MRK +2.7%) ($48), Johnson & Johnson (JNJ +0.7%) ($85), Eli Lilly (LLY +1.4%) ($44), Bristol-Myers Squibb (BMY +0.5%) ($45), AbbVie (ABBV +1.2%) ($50), and Abbot Laboratories (ABT +1.1%) ($42). "We remain positive on pharmaceuticals," Jefferies says, "valuation is attractive for most stocks." 6 Comments [Healthcare]
Wednesday, April 10, 12:28 PM Jim Cramer likes what he sees in Merck (MRK +2.1%) right now, saying the stock is lagging its peers, trading at just about 12x earnings versus a richer 14x the rest of the sector. Patent cliff fears for this stock are pretty well mitigated, Cramer says. The company has no fewer than five solid drugs in development, and while none may be a home run, the pipeline should bolster growth over the next few years. He thinks the stock should be trading somewhere closer $60 right now. 1 Comment [Healthcare, On the Move]
Wednesday, April 10, 8:48 AM The FDA accepts Merck's (MRK) NDA application for a tablet version of the company's Noxafil antifungal medicine, which it already markets in an oral liquid form. (PR) Comment! [Healthcare]
Thursday, April 4, 4:45 AM The cost of caring for people with dementia is $157-215B a year and could double by 2040, a study from RAND Corp. estimates. The cost of dementia treatment is $109B - above the $102B spent on heart disease and the $77B on cancer - with the other dementia expenses used for long-term day-to-day care. Companies that develop drugs for Alzheimer's disease and other conditions include Pfizer (PFE), Eli Lilly (LLY), J&J (JNJ) and Merck (MRK). 5 Comments [Healthcare]

Gare17
Check out my article : http://seekingalpha.com/p/137f5 $NVS $MRK $PFE $ZLCS
May 6, 1:08 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ltfinger
New Downgrades (5/1/13): $BC, $EPD, $LGCY, $MRK, $OLN, $ONXX, $SPB, $SSI, $THOR, $TRGP, $TUP
May 2, 10:26 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Jermanis
Good thing CNBC was pumping $MRK recently.
May 1, 9:05 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

IALF
$LXRX looks to be down due to $MRK and $PFE deal. Time to find a new bottom.
Apr 29, 10:49 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Chines33
Reviewing the schedule this week Wednesday looms big. $MA $V $FB $ADT $MAR $HOT $LVS $VIA-B $CHK $MRK $PSX $CLX and the Fed.
Apr 28, 5:12 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Gare17
If we don't hear from $ZLCS next Monday or Tuesday with Novartis renewal I think buyout rumors will start .. $NVS $MRK $PFE #Ions
Apr 26, 12:43 PM
Reply (1)

• !Report Abuse
View all 1 replies
Gare17: $ZLCS buyout or spinoff with $NVS for Chts technology
Apr 29, 4:17 PM
• !Report Abuse
Add a reply...

140 characters

Tony Kau
$MRK seeing exhaustion here, TE Score: -6 http://ow.ly/klp9z http://ow.ly/i/1Xd4G
Apr 23, 12:18 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Nathaniel Matherson
Buy This Stock On Relative Weakness: $MRK $LLY $GSK http://bit.ly/YRKc3U
Apr 16, 7:46 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Bio Matt
Current biotech/pharma portfolio: $ALXA $SRPT $AMBS $GALE $ONCS $RAFA $MRK
Apr 13, 8:12 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Chines33
Favorite longs remain $MRK $PFE $HRB willing to add. Other longs I'm looking add starting/re adding:
Apr 3, 8:56 PM
Reply (4)

• !Report Abuse
View all 4 replies
Noreika: Glad to see you back Chines
Apr 4, 7:27 AM
• !Report Abuse
Chines33: Thanks.
Apr 4, 4:05 PM
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

Gare17
If we don't hear from $ZLCS next Monday or Tuesday with Novartis renewal I think buyout rumors will start .. $NVS $MRK $PFE #Ions
Apr 26, 12:43 PM
Reply (1)

• !Report Abuse
View all 1 replies
Gare17: $ZLCS buyout or spinoff with $NVS for Chts technology
Apr 29, 4:17 PM
• !Report Abuse
Add a reply...

140 characters

Chines33
Favorite longs remain $MRK $PFE $HRB willing to add. Other longs I'm looking add starting/re adding:
Apr 3, 8:56 PM
Reply (4)

• !Report Abuse
View all 4 replies
Noreika: Glad to see you back Chines
Apr 4, 7:27 AM
• !Report Abuse
Chines33: Thanks.
Apr 4, 4:05 PM
• !Report Abuse
Add a reply...

140 characters

Chines33
Mentioned last night long $MRK broke out yesterday up today in a down tape.
Apr 3, 7:44 PM
Reply (1)

• !Report Abuse
View all 1 replies
Chines33: Never had a chance this am to short $AMGN against it. would have been a sweet pair.
Apr 3, 7:45 PM
• !Report Abuse
Add a reply...

140 characters

Chines33
$MRK breakout today. Looking to add more.
Apr 2, 8:02 PM
Reply (2)

• !Report Abuse
View all 2 replies
Chines33: Would like to short $AMGN against it short term for some mean revision.
Apr 2, 8:03 PM
• !Report Abuse
Chines33: Almost reshorted it on the close but will wait to see what happens at open.
Apr 2, 8:04 PM
• !Report Abuse
Add a reply...

140 characters

SKS1586
Bought-$VMW,$EMC,$CY,$CSCO,$INTC,$MSFT,$IBM,$CLF,$CCJ,$FCX,$SCCO,$SWC,$WFC,$CJES,$ECA,$DPM,$BP,$MRK,$UNH,$BRLI,$KO,$SYY,$CHRW,$VOD,$JOY,$HMC
Feb 25, 4:53 PM
Reply (15)

• !Report Abuse
View all 15 replies
SKS1586: andyk80: Mr Market is listening to you & following your thought of bounce, with uptick in all the Futures @ this moment.
Feb 25, 8:19 PM
• !Report Abuse
SKS1586: I diversified my buys in all the sectors today. My unhappy buys are Platinum ($SWC), Copper ($SCCO, $FCX), Energy ($BP,$DVN,$ECA,$DPM,$KBR).
Feb 25, 8:26 PM
• !Report Abuse
Add a reply...

140 characters

SKS1586
Sold $YNDX, $WFC, $WEN, $SYY, $SIMG, $QUIK, $MRK, $ABT, $KSS, $DELL to keep Profit & create CASH for next week trading.
Feb 22, 3:15 PM
Reply (2)

• !Report Abuse
View all 2 replies
joe kelly: Why $YNDX? Looks great long. Am I missing something? Long YNDX
Feb 22, 3:42 PM
• !Report Abuse
SKS1586: joe kelly - I reduce or remove my positions for creation of CASH. Therefore I leave trades with much less profit than most Investors/Traders
Feb 22, 7:33 PM
• !Report Abuse
Add a reply...

140 characters

Ryan Mallory
16 Defensive Stock Plays to Weather Market Uncertainty http://bit.ly/RVR8Ko AAPL ABT AMZN AZN MRK NVS PEP to name a few of them
8/28/12
Reply (1)

• !Report Abuse
View all 1 replies
driftking27: How do you see the strong CHf affecting there growth. I think that could be one hurdle that could hurt there sales. Plus NVS drops more...
10/25/12
• !Report Abuse
Add a reply...

140 characters

J. Sheehan
MRK has set a new 52 week high 8 of the last 13 days.
10/18/12
Reply (6)

• !Report Abuse
View all 6 replies
J. Sheehan: In @ $35.05, and plan on holding unless something crazy happens. Might take some profits before Q412 ER.
10/18/12
• !Report Abuse
J. Sheehan: I know prescriptions for Singulair were down 90% in the U.S. just a month after U.S. patent expiration in August.
10/18/12
• !Report Abuse
Add a reply...

140 characters

David Crosetti
It's a beautiful day in the neighborhood! Great rally! Rebalancing the portfolio today! Hot dog! MRK up 4%?? Wow.
7/27/12
Reply (6)

• !Report Abuse
View all 6 replies
A Newell: Yes...MRK is supposed to be stoggy but stable. Amazing grace.
7/29/12
• !Report Abuse
David Crosetti: Had a nice run of Friday, Newell!
7/29/12
• !Report Abuse
Add a reply...

140 characters

The_American
GSK DNDN TNGN.OB CTIC STEM should ALL be looked at into the BIB space and PFE MRK GSK should be looking into much more MDT also looking AMRS X
4/21/12
Reply (6)

• !Report Abuse
View all 6 replies
The_American: No long GLD GSK starred at it long NUGT Miners showing bottom GDX GDXJ GLDX RING and GGGG The GLD IAU SLV AGQ DBS CEF MUX HL SWC DIA QQQ AA
5/18/12
• !Report Abuse
The_American: No long GLD GSK starred at it long NUGT Miners showing bottom GDX GDXJ GLDX RING and GGGG The GLD IAU SLV AGQ DBS CEF MUX HL SWC DIA QQQ AA
5/18/12
• !Report Abuse
Add a reply...

140 characters

FortSumter
Playing the bitotech lottery with a play on IDIX. Buy out by MRK maybe? Big month ahead.
2/13/12
Reply (13)

• !Report Abuse
View all 13 replies
John Rayhall: IDIX has a huge buyout premium in already was 7 before the INHX buyout. Any bad news and it'll get crushed.
2/23/12
• !Report Abuse
John Rayhall: Nice trading :)
2/23/12
• !Report Abuse
Add a reply...

140 characters

Dividend Sheet
Best Healthcare Stock Picks For 2012: http://bit.ly/w32xHl + $MRK $NVS $STJ $TEVA $TMO $CELG $GILD
12/24/11
Reply (2)

• !Report Abuse
View all 2 replies
Ocean Man: I agree w/ NVS and STJ. I'd add SNY.
12/25/11
• !Report Abuse
mitrado: $MRK over 37.5 is quite a suicidal choice... it can go up to 50, but it can as easily fall back to 30... :-/
1/19/12
• !Report Abuse
Add a reply...

140 characters

BK0324
would you sell your MRK today for an $800 profit or hold on for more ....
12/22/11
Reply (2)

• !Report Abuse
View all 2 replies
Ocean Man: I would sell half in that situation.
12/22/11
• !Report Abuse
BK0324: Exactly what I did!! ;)
12/22/11
• !Report Abuse
Add a reply...

140 characters

BK0324
would you sell your MRK today for an $800 profit or hold on for more .... about 6% profit
12/22/11
Reply (9)

• !Report Abuse
View all 9 replies
mitrado: I guess I didn't want to take that risk a 3rd time.
12/22/11
• !Report Abuse
FortSumter: Out today at $37.50. Just based on technicals there will soon be another entry point.
12/22/11
• !Report Abuse
Add a reply...

140 characters

Rocket Robin
ex-div tomorrow for $MRK $SJR $RCI
12/12/11
Reply (2)

• !Report Abuse
View all 2 replies
BK0324: MRK is down quite a bit, I wish I had money to add some more ....
12/12/11
• !Report Abuse
Rocket Robin: $SJR is a good deal considering today's down. 4.6% div is good too :)
12/12/11
• !Report Abuse
Add a reply...

140 characters

MRK Merck & Co Inc.

MRK

Merck & Co Inc.